CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −8,659 | $32.04 | $277K | 52,028 |
| 2025-06-03 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,610 |
| 2025-06-03 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $31.88 | $64K | 140,610 |
| 2025-06-03 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 19,105 | ||
| 2025-06-02 | Lee Sung EVP, Chief Financial Officer | Shares withheld for taxes | −4,965 | $31.21 | $155K | 69,477 |
| 2025-06-02 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $31.22 | $156K | 408,108 |
| 2025-05-20 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,000 | $10.60 | $21K | 142,255 |
| 2025-05-20 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $31.98 | $64K | 140,255 |
| 2025-05-20 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −2,000 | 21,105 | ||
| 2025-05-16 | Blum Robert I President & CEO | Sale 10b5-1 | −5,000 | $30.93 | $155K | 412,629 |
| 2025-05-15 | Bhanji Muna Director | Sale 10b5-1 | −1,454 | $29.73 | $43K | 23,510 |
| 2025-05-14 | Harrington Robert Arthur Director | Grant or award | +7,333 | 22,315 | ||
| 2025-05-14 | Harrington Robert Arthur Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,880 | 10,880 | ||
| 2025-05-14 | PARSHALL B LYNNE Director | Grant or award | +7,333 | 27,933 | ||
| 2025-05-14 | PARSHALL B LYNNE Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,880 | 10,880 | ||
| 2025-05-14 | Bhanji Muna Director | Grant or award | +7,333 | 24,964 | ||
| 2025-05-14 | Bhanji Muna Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,880 | 10,880 | ||
| 2025-05-14 | HENDERSON JOHN T Director | Grant or award | +7,333 | 73,681 | ||
| 2025-05-14 | HENDERSON JOHN T Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,880 | 10,880 | ||
| 2025-05-14 | Kaye Edward M. MD Director | Grant or award | +7,333 | 33,294 |
Page 19 of 22 · 429 trades